MedTrace Logo

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

NCT00199849 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-10-10

Study results available
· View outcomes & findings →

Summary

To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.

Conditions

Interventions

BIOLOGICAL

NY-ESO-1 Plasmid DNA Cancer Vaccine

NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.

Sponsors & Collaborators

  • New York Presbyterian Hospital

    collaborator OTHER

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    collaborator OTHER

  • Ludwig Institute for Cancer Research

    lead OTHER

Principal Investigators

  • Padmanee Sharma, MD PhD · UT MD Anderson Cancer Center Genitourinary Med Onc

  • Nasser K Altorki, MD · Weill Medical College of Cornell University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-27
Primary Completion
2006-09-11
Completion
2007-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199849 on ClinicalTrials.gov